Sherbrooke Park Advisers LLC Tango Therapeutics, Inc. Transaction History
Sherbrooke Park Advisers LLC
- $313 Billion
- Q4 2024
A detailed history of Sherbrooke Park Advisers LLC transactions in Tango Therapeutics, Inc. stock. As of the latest transaction made, Sherbrooke Park Advisers LLC holds 12,307 shares of TNGX stock, worth $30,398. This represents 0.01% of its overall portfolio holdings.
Number of Shares
12,307Holding current value
$30,398% of portfolio
0.01%Shares
2 transactions
Others Institutions Holding TNGX
# of Institutions
135Shares Held
92.6MCall Options Held
3.1KPut Options Held
1.5K-
Trv Gp Iv, LLC Boston, MA16.9MShares$41.6 Million64.97% of portfolio
-
Tcg Crossover Management, LLC Palo Alto, CA10.7MShares$26.5 Million5.42% of portfolio
-
Eco R1 Capital, LLC San Francisco, CA10.6MShares$26.3 Million1.53% of portfolio
-
Nextech Invest Ag5.53MShares$13.7 Million3.19% of portfolio
-
Farallon Capital Management LLC San Francisco, CA4MShares$9.88 Million0.07% of portfolio
About Tango Therapeutics, Inc.
- Ticker TNGX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 88,067,296
- Market Cap $218M
- Description
- Tango Therapeutics, Inc., a biotechnology company, discovers and develops drugs for the treatment of cancer. Its lead program is TNG908, a synthetic lethal small molecule inhibitor of protein arginine methyltransferase 5 that is being developed as a treatment for cancers with methylthioadenosine phosphorylase deletions. The company also develops...